Brief: Tissuecypher® Outperforms Pathologist Diagnoses When Predicting Progression In Patients Diagnosed With Barrett’S Esophagus With Low-Grade Dysplasia

Castle Biosciences

24/05/2022 23:21

May 24 (Reuters) - Castle Biosciences Inc  CSTL.O :
    * TISSUECYPHER® OUTPERFORMS PATHOLOGIST DIAGNOSES WHEN
PREDICTING
PROGRESSION IN PATIENTS DIAGNOSED WITH BARRETT’S ESOPHAGUS WITH
LOW-GRADE DYSPLASIA
    * CASTLE BIOSCIENCES INC - NEW STUDY DATA PRESENTED AT
DIGESTIVE
DISEASE WEEK (DDW) 2022
    * CASTLE BIOSCIENCES - TISSUECYPHER OUTPERFORMED STANDARD OF
CARE
IN PREDICTING MALIGNANT PROGRESSION IN SURVEILLANCE BIOPSIES
FROM 154 BE PATIENTS

Source text for Eikon:  ID:nBwbBnJf5a 
Further company coverage:  CSTL.O 

 ((Reuters.Briefs@thomsonreuters.com;))